CEO Update | 13 March 2023

What a weekend. The strategic risk to our sector resulting from the run on Silicon Valley Bank (SVB) has been averted. HSBC has come in to buy SVB UK and we now have a major UK bank supporting our growing industry for the years ahead.

Thank you to all who have worked so hard to get us to this point, and for the engagement, insight and trust our members had in the BIA.

Without you sharing the size of the problem, I don’t think we could have made such a convincing case to the UK government for such a strategic intervention.

It’s been a rollercoaster and I’ll need some time to assimilate. I hope to write a fuller story on this in the weeks ahead.

See our initial statement on this matter, the statement from the HM Treasury and Bank of England and from HSBC.

Media reports worth a look are below. 

I’m sure many of you will never forget this weekend and how close to disaster we all sailed. Do share your thanks and tales of relief (and what you continue to do) with partners and stakeholders as we go forward.

Onward now to the Spring Budget on Wednesday, R&D tax credits and VPAS.

Steve Bates Headshot.png



Steve Bates OBE
CEO, BioIndustry Association

More news and updates

CEO Update | 27 March 2023

The UK Government published last week the long-awaited response to the consultation on proposals to improve the UK clinical trials legislation, with a foreword by life science champions Sir John Bell and Sir Jon Symonds. These reforms represent the biggest overhaul in UK clinical trials regulation in over 20 years and will make the UK one of the best countries to conduct clinical research for the benefit of patients and the life sciences sector. Continue reading for details on upcoming events, UK Parliament scrutiny of SVB Collapse, and more.

Revolutionising healthcare with data-driven innovation

Meet Danny Bosch, Associate Director of Business Development and Commercial at Imperial College Health Partners (ICHP). In his blog, Danny details how ICHP are working towards creating healthier populations, by unlocking the potential of innovation and supporting NHS and industry. 

Macomics and Ono Pharmaceutical partner to discover and develop macrophage-targeting antibody therapy for the treatment of cancer

Worldwide drug discovery collaboration agreement with Ono to develop new antibody drugs against a novel macrophage target of interest in immuno-oncology

Brainomix receives FDA clearance for its flagship stroke AI imaging software

The Oxford, UK headquartered company, long established as a market leader in Europe and a pioneer in the development of innovative stroke AI solutions, is now poised to take its transformative technology to US stroke centers

Unlocking the power of Virtual Reality to overcome anxiety and phobias

XR Therapeutics is a start-up company, spun out of Newcastle University, helping people to overcome their phobias or anxiety using Virtual Reality technology. We spoke with Penny Day, Head of Operations, about the role of virtual reality in mental health treatment, and how XR is making waves in this space.

CEO Update | 20 March 2023

The Budget last week had major wins for BIA members including changes to R&D tax credits rates for loss-making SMEs. Read our press release and Martin’s analysis blog. This is a major, major win for a BIA campaign and wouldn’t have happened without member engagement and perseverance. Many thanks to all who helped – this non dilutive government co-investment will make all the difference as you crowd in private sector investment.

More within